Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Sees Significant Decline in Short Interest
Calidi Biotherapeutics (NYSEAMERICAN:CLDI) reported short interest fell to 670,614 shares as of May 15, down 77.9% from 3,038,967 on April 30, with 6.4% of shares sold short and a 0.3 days-to-cover ratio. The stock traded at $0.19, down 2.6%. The company reported EPS of -$0.43 for the quarter ended May 14, and institutional holders own 12.53%.
How this was made
The 30-second read
Why it matters
A large drop in short interest and a 0.3 days-to-cover ratio typically lowers the probability of a near-term short squeeze, shifting focus back to clinical/financing catalysts rather than positioning.
Market read
Traders may adjust tactical exposure based on reduced short pressure, but the article provides no new clinical outcome or guidance catalyst.
What to watch
The article doesn’t explain why shorts reduced exposure; with very low market cap and thin liquidity, price can still gap on small flows.
Background
The piece summarizes May short-interest levels for Calidi Biotherapeutics and notes recent institutional ownership changes plus the latest trading snapshot and last reported EPS.
Ticker impact
CLDI’s short interest fell 77.9% in May, with days-to-cover dropping to 0.3, signaling reduced short pressure.
Near-term bias slightly lower/neutral versus a short-squeeze setup; any move likely driven by liquidity and biotech risk rather than shorts.
The article provides a large reduction in short interest and very low days-to-cover, which typically reduces the probability of a squeeze, but it does not tie the change to new fundamental catalysts.
Market effects
Limited direct sector impact; this is company-specific positioning data rather than a biotech-wide catalyst.
None indicated; US micro-cap liquidity dynamics dominate.
None indicated.
Counterpoint
Short interest can fall because shorts exit on liquidity/financing concerns rather than improved fundamentals, so price may not follow.
Key entities
- companyCalidi Biotherapeutics, Inc.
Clinical-stage biotech; subject of the short-interest decline and trading snapshot.
- investor_groupInstitutional investors/hedge funds
Reported to have modified holdings, with Geode Capital Management increasing and other funds initiating small stakes.
